Si está buscando comprar medicamentos en línea en España, es importante elegir una farmacia en línea de confianza y segura para garantizar que los medicamentos que reciba sean auténticos y de alta calidad. En comprar-farmacia.es, ofrecemos una amplia selección de medicamentos, incluido Cialis para la disfunción eréctil (DE), y trabajamos con farmacias acreditadas para garantizar la calidad y la autenticidad de nuestros productos.
Visite nuestro sitio web en comprar-farmacia.es para obtener más información sobre nuestros productos y servicios. Nuestro equipo de atención al cliente está disponible para ayudarlo en todo momento y garantizar una experiencia de compra en línea segura y satisfactoria.
Untitled
A novel two-step kit for topical treatment of tinea pedis –an open study
A Shemer,† MH Grunwald,‡ B Davidovici,§ N Nathansohn,† B Amichai†,*
†Department of Dermatology, Sheba Medical Center, Tel-Hashomer, ‡Soroka University Medical Center, Ben-Gurion University,Beer-Sheva, and §Dermatology Unit, Kaplan Medical Center, Rehovot, Israel
*Correspondence: B Amichai. E-mail: [email protected]
AbstractBackground Tinea pedis is a common skin disease affecting most of the population during their lifetime. Topical
and systemic treatments give only temporary relief.
Objective To evaluate the efficacy and safety of a new topical treatment for moderate-to-severe tinea pedis.
Methods Fifty patients suffering from tinea pedis were treated in two stages: the active stage – single use of the
novel topical solution for 45 min and novel cream twice weekly for 4 weeks; the preventive stage – cream
application once weekly for 10 months.
Results Forty-five patients completed the active stage and achieved 76% cure rate. The medication was well
tolerated; one patient dropped from the study because of very mild irritation. No other topical or systemic side
effects were noted. Another five patients were lost to follow-up during the preventive stage. The total cure rate after
Conclusions This novel treatment was found to be effective, well tolerated and safe in the treatment of moderate
and severe tinea pedis during the active and the preventive stages.
Received: 27 October 2009; Accepted 18 December 2009
Tinea pedis is a common fungal infection in adults, affectingbetween 30% and 70% of the population.1,2 It often develops in
persons with hyperhidrosis,3 particularly among men between 20
Fifty patients, males and females suffering from moderate-to-
and 40 years of age.4 Elderly, diabetic and immunocompromised
severe tinea pedis (moccasin type, interdigitalis type and vesiculob-
patients are also at risk.4 The aetiologic pathogens most commonly
ulous type) confirmed by mycological direct smear and culture
associated with tinea pedis are Trichophyton rubrum, Trichophyton
were enrolled in the study. Patients suffering from diabetic or
mentagrophytes and Epidermophyton floccosum.1–5
stasis ulcers, peripheral vascular diseases or plantar keratoderma
Fungal infection has a tendency to colonize the outer layer of
including psoriasis were excluded. Pregnant and lactating women
the skin, the stratum corneum. This layer serves as a reservoir of
were also excluded. All patients stopped any topical or systemic
food for fungi. Under conditions of moisture and the warm envi-
antifungal treatment 4 months before entering the study. Patients
ronment of the soles, the reaction between the fungus and the stra-
known to have an allergy to at least one of the components of
tum corneum produces a foul smelling odour. Itching, especially
between the toes, is a very common complaint.3
Tinea pedis was confirmed by both KOH examination and
Following effective treatment, patients return after several weeks
mycological cultures of samples taken from the affected skin. Sam-
to months with the same complaint; therefore, preventive treat-
ples were divided into two parts; one was used for direct KOH
ment is required. In this study, we evaluated the efficacy and safety
examination and the second for fungal culture using Sabouraud’s
of a new topical antifungal medication.
Dextrose Agar (Novamed, Jerusalem, Israel) that contains
Journal compilation ª 2010 European Academy of Dermatology and Venereology
chloramphenicol and penicillin to prevent bacterial contamina-
patients (76%) had complete cure, two patients had marked
tion. Identification of the fungus is done on the basis of micro-
improvement, three patients had moderate improvement and two
scopic morphological characteristics of the different fungi.
patients had mild improvement of their soles’ skin condition(Table 1).
Ten months later (after the preventive stage), the patients were
The medication used in our study was a two-step kit: PedicureÔ
re-examined and the findings were as follows: 35 (70%) patients
Solution & PedicureÔ Cream (Pedicure Ltd., Tel-Aviv, Israel).
had no pathological finding – mycological analyses were negative
The active ingredients in the solution were 0.5% climbazole
(Fig. 1), 1 (2%) patient had slight dryness – mycological analysis
and 14% glycolic acid 70%, and in the cream 0.5% climbazole and
was negative for both direct smear and culture. Four (8%) patients
had recurrence of the both clinical and mycological findings. Fivepatients were lost to follow-up (Table 2).
The study was conducted according the rules of the local HelsinkiCommittee and all patients provided written informed consentbefore enrolment.
Table 1 Results of treatment at the end of the active stage
Classification of the severity of the disease was based on a 0–3
score of the parameters used by de Chauvin et al.6; 0 = none,
1 = mild, 2 = moderate, 3 = severe. The score was based on
clinical signs and symptoms (erythema, desquamation, pruritus,
pustules, vesiculation and incrustation) scored by the investigator
Treatment was divided into two stages: active and preventive.
Active stage. A single treatment with the solution (Pedicuresolution); patients were instructed to put their feet in plastic bagsfilled with the solution for 45 min after which the feet were driedwith a towel. The cream (Pedicure cream) was applied twiceweekly for 4 weeks overnight for 6–8 h. The patients were askedto record any topical and ⁄ or systemic side effects that appearedduring treatment.
After 4 weeks of treatment (the active stage), the patients were
re-examined clinically and mycologically (KOH examination andfungal culture) by the same physician; the improvement grade andside effects were evaluated.
Preventive stage. After the active stage, the cream wasapplied once weekly for 10 months. Patients were evaluated(clinically and mycologically) at the end of this preventive stage.
Each patient was assessed using the following score: total cure –
both clinical and mycological cure; marked improvement – more
Before treatment After treatment
than 75% clinical cure; moderate improvement – 50–74% clinical
Figure 1 Clinical picture showing results of treatment.
cure; mild improvement – 25–49% clinical cure; and failure – incases of 0–24% change. Worsening – if the clinical findings worsencompared with baseline.
Table 2 Results of treatment at the end of the preventive stage
Of 50 patients, 24 men (mean age 42.5 years) and 26 women
(mean age 47.1 years), suffering from moderate-to-severe tinea
pedis, 45 patients completed the active stage, four patients did not
return for follow-up and one patient experienced slight stinging
after 20–30 min of treatment with the solution and discontinued
the treatment. Of the 45 patients who completed the first stage, 38
Journal compilation ª 2010 European Academy of Dermatology and Venereology
pedis with terbinafine and clotrimazole showed good efficacy of
In tinea pedis, the fungal infection is localized in the stratum
75–80%, but the relapse rate in patients treated with terbinafine
corneum, which serves as reservoir of food for fungi. Most of the
was 15% and among clotrimazole patients, it was 19%. Savin and
topical agents used in the treatment of tinea pedis usually have
Jorizzo12 found that sertaconazole nitrate cream gave 70% myco-
only fungicidic or fungistatic properties. The two-step kit used in
logical cure after 4 weeks of treatment, but 2 weeks after cessation
our study was composed of two types of active ingredients:
of treatment only 47% remained mycological cure. This finding
antifungal – climbazole, and keratolitic agents glycolic acid and
stressed the need of prophylactic use of topical antifungal treat-
urea, which were used to remove scales of stratum corneum.
ment. In our study, we showed similar cure rates at the end of the
Climbazole (1-(4-chlorophenoxy)-1-(imidazole-1-yl) 3,3-dim-
active stage of treatment, but prophylactic use of the medication
ethylbutan-2-one) is an imidazole antifungal. Azole antifungals
prevent the synthesis of ergosterol, the major sterol component offungal plasma membranes, by inhibiting the cytochrome P450
(CYP450)-dependent enzyme lanosterol 14-a-demethylase. The
1 Gupta AK, Tu LQ. Therapies for onychomycosis: a review. Dermatol
subsequent depletion of ergosterol interferes with the structural
2 Baran R, Kaoukhov A. Topical antifungal drugs for the treatment of
function of fungal membranes leading to leakage of cell contents.
onychomycosis: an overview of current strategies for monotherapy
The net result is an inhibition of fungal growth and replication.7,8
and combination therapy. J Eur Acad Dermatol Venereol 2005; 19:
Secondary effects, such as inhibition of the morphogenetic trans-
3 Masri-fridling GD. Dermatophytosis of the feet. Dermatol Clin 1996;
formation of yeasts to the mycelial form, decreased fungal adher-
ence and direct toxic effects on membrane phospholipids have
4 Zuber TJ, Baddam K. Superficial fungal infection of the skin. Where
been reported in the literature.9 As azole antifungals, at therapeutic
and how it appears help determine therapy. Postgrad Med 2001; 109:
concentrations, bind more tightly to the fungal CYP450-depen-
5 Noble SL, Forbes RC, Stamm PL. Diagnosis and management of
dent enzyme lanosterol 14-a-demethylase than to the mammalian
common tinea infection. Am Fam Phys 1998; 58: 163–174.
enzyme,7 these compounds are considered safe for a variety of
6 de Chauvin MF, Viguie´-Vallanet C, Kienzler JL, Larnier C. Novel,
single-dose, topical treatment of tinea pedis using terbinafine: results of
The results of this study indicate that the above outlined treat-
a dose-finding clinical trial. Mycoses 2008; 51: 1–6.
7 Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole
ment was satisfactory in the treatment of fungal infection of the
antifungal agents. Clin Microbiol Rev 1999; 12: 40–79.
soles during both active and preventive stages. The treatment was
8 Maertens JA. History of the development of azole derivatives. Clin
well tolerated and no significant side effects were noted. Compli-
Microbiol Infect 2004; 10(Suppl. 1): 1–10.
ance with treatment is enhanced by the fact that the treatment
9 Como JA, Dismukes WE. Oral azole drugs as systemic antifungal
therapy. N Engl J Med 1994; 330: 263–272.
regimen does not require daily application of the drug. This novel
10 Albanese G, Di Di Cintio R, Giorgetti P, Galbiati G, Ciampini M.
treatment was based on combined antifungal compounds and
Recurrent tinea pedis: a double blind study on the prophylactic use of
keratolitic agents, which probably acted synergistically.
fenticonazole powder. Mycoses 1992; 35: 157–159.
Tinea pedis is extremely difficult to eradicate, as there are per-
11 Patel A, Brookman SD, Bullen MU et al. Topical treatment of
interdigital tinea pedis: terbinafine compared with clotrimazole.
sistence conditions, mainly maceration, continuous use of topical
Australas J Dermatol 1999; 40: 197–200.
antifungal medication is effective as a preventive therapy against
12 Savin R, Jorizzo J. The safety and efficacy of sertaconazole nitrate
recurrences.10 Patel et al.11 reported that topical treatment of tinea
cream 2% for tinea pedis. Cutis 2006; 78: 268–274.
Journal compilation ª 2010 European Academy of Dermatology and Venereology
Inside this issue: Greetings to all and welcome to issue three of the YDPSA newsletter. The YDPSA has progressed tremendously since the elections of this current committee. This new committee hopes to achieve the unity and goals of the tawheed faith. To do this we have organised certain events for the term of this committee. Some of the forthcoming events include a trip to the Riverland